Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 7/2017

01-07-2017 | Review

The immunological function of CD52 and its targeting in organ transplantation

Authors: Yang Zhao, Huiting Su, Xiaofei Shen, Junfeng Du, Xiaodong Zhang, Yong Zhao

Published in: Inflammation Research | Issue 7/2017

Login to get access

Abstract

Introduction

CD52 (Campath-1 antigen), a glycoprotein of 12 amino acids anchored to glycosylphosphatidylinositol, is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs). The anti-CD52 mAb, alemtuzumab, was used widely in clinics for the treatment of patients such as organ transplantation. In the present manuscript, we will briefly summarize the immunological function of CD52 and discuss the application of anti-CD52 mAb in transplantation settings.

Findings

We reviewed studies published until July 2016 to explore the role of CD52 in immune cell function and its implication in organ transplantation. We showed that ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation. However, soluble CD52 molecules will interact with the inhibitory sialic acid-binding immunoglobulin-like lectin 10 (Siglec10) to significantly inhibit T cell proliferation and activation. Although the physiological and pathological significances of CD52 molecules are still poorly understood, the anti-CD52 mAb, alemtuzumab, was used widely for the treatment of patients with chronic lymphocytic leukemia, autoimmune diseases as well as cell and organ transplantation in clinics.

Conclusion

Studies clearly showed that CD52 can modulate T-cell activation either by its intracellular signal pathways or by the interaction of soluble CD52 and Siglec-10 expressing on T cells. However, the regulatory functions of CD52 on other immune cell subpopulations in organ transplantation require to be studied in the near future.
Literature
1.
2.
Xia MQ, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J. 1993;293(Pt 3):633–40.PubMedPubMedCentralCrossRef
3.
Cheetham GM, et al. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J Mol Biol. 1998;284(1):85–99.PubMedCrossRef
4.
Kirchhoff C, et al. A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone. Mol Reprod Dev. 1993;34(1):8–15.PubMedCrossRef
5.
Buggins AG, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002;100(5):1715–20.PubMed
6.
Ratzinger G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003;101(4):1422–9.PubMedCrossRef
7.
Hale G. The CD52 antigen and development of the CAMPATH antibodies. CytoTherapy. 2001;3(3):137–43.PubMedCrossRef
8.
9.
Cohen JA, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28.PubMedCrossRef
10.
Garnock-Jones KP. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. Drugs. 2014;74(4):489–504.PubMedCrossRef
11.
Fox EJ, et al. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci. 2016;363:188–94.PubMedCrossRef
12.
Hui YM, et al. Use of non-irradiated blood components in Campath (alemtuzumab)-treated renal transplant patients. Transfus Med. 2016;26(2):138–46.PubMedCrossRef
13.
Schub N, et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011;46(1):143–7.PubMedCrossRef
14.
Li SW, et al. All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia. Blood. 2003;101(5):1977–80.PubMedCrossRef
15.
Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82(3):807–12.PubMed
16.
Elsner J, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood. 1996;88(12):4684–93.PubMed
17.
Knechtle SJ, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery. 2004;136(4):754–60.PubMedCrossRef
18.
Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood. 2009;114(14):3052–5.PubMedCrossRef
19.
20.
Olweus J, Lund-Johansen F, Terstappen LW. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods. 1994;5(3):179–88.PubMedCrossRef
21.
Williams RJ, et al. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G. CytoTherapy. 2000;2(1):5–14.PubMedCrossRef
22.
Xia MQ, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol. 1991;21(7):1677–84.PubMedCrossRef
23.
Bandala-Sanchez E, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14(7):741–8.PubMedCrossRef
24.
Rowan W, et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998;95(3):427–36.PubMedPubMedCentralCrossRef
25.
Nuckel H, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol. 2005;514(2–3):217–24.PubMedCrossRef
26.
Mone AP, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 2006;20(2):272–9.PubMedCrossRef
27.
Smolewski P, et al. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res. 2006;30(12):1521–9.PubMedCrossRef
28.
Nguyen TH, et al. Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes. Leuk Lymphoma. 2012;53(4):699–709.PubMedCrossRef
29.
Rowan WC, et al. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol. 1995;7(1):69–77.PubMedCrossRef
30.
Hederer RA, et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol. 2000;12(4):505–16.PubMedCrossRef
31.
Masuyama J, et al. A novel costimulation pathway via the 4C8 antigen for the induction of CD4 + regulatory T cells. J Immunol. 2002;169(7):3710–6.PubMedCrossRef
32.
Masuyama J, et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med. 1999;189(6):979–90.PubMedPubMedCentralCrossRef
33.
Watanabe T, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol. 2006;120(3):247–59.PubMedCrossRef
34.
Pant AB, et al. Alteration of CD39+ Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment. J Neuroimmunol. 2017;303:22–30.PubMedCrossRef
35.
Shah A, et al. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro. Transpl Int. 2006;19(9):749–58.PubMedCrossRef
36.
37.
38.
Lowenstein H, et al. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. Transpl Int. 2006;19(11):927–36.PubMedCrossRef
39.
Stauch D, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One. 2009;4(3):e4709.PubMedPubMedCentralCrossRef
40.
Shen B, et al. Impact of antimouse CD52 monoclonal antibody on Graft’s gamma delta intraepithelial lymphocytes after orthotopic small bowel transplantation in Mice. Transplantation. 2013;95(5):663–70.PubMedCrossRef
41.
Rodig SJ, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006;12(23):7174–9.PubMedCrossRef
42.
Dearden CE, Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Practice Research Clinical Haematology. 2006;19(4):795–810.PubMedCrossRef
43.
Cabrera R, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis c in liver transplant patients. Liver Transplant. 2009;15(2):216–22.CrossRef
44.
Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant Int. 2006;19(9):705–14.CrossRef
45.
46.
Zhang X, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (Anti-CD52 Monoclonal Antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191(12):5867–74.PubMedCrossRef
47.
Jones JL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133:2232–47.PubMedCrossRef
48.
Chakraverty R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99(3):1071–8.PubMedCrossRef
49.
Kottaridis PD, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96(7):2419–25.PubMed
50.
Kirsch BM, et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol. 2006;16(3–4):254–7.PubMedCrossRef
51.
Klangsinsirikul P, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99(7):2586–91.PubMedCrossRef
52.
Siders WM, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma. 2010;51(7):1293–304.PubMedCrossRef
53.
Gorin NC, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol. 2013;91(4):315–21.PubMed
54.
Neerukonda AR, et al. refractory adult primary autoimmune neutropenia that responded to Alemtuzumab. Intern Med. 2016;55(12):1667–70.PubMedCrossRef
55.
Masuyama J, et al. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies. CytoTherapy. 2016;18(1):80–90.PubMedCrossRef
56.
Naparstek E, et al. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp Hematol. 1999;27(7):1210–8.PubMedCrossRef
57.
Dyer MJ, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73(6):1431–9.PubMed
58.
Hale G, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. The Lancet. 1988;2(8625):1394–9.CrossRef
59.
Ciancio G, et al. The use of campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation. 2004;78(3):426–33.PubMedCrossRef
60.
Kirk AD, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation. 2003;76(1):120–9.PubMedCrossRef
61.
Bloom DD, et al. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation. 2006;81(1):81–7.PubMedCrossRef
62.
Knechtle SJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003;3(6):722–30.PubMedCrossRef
63.
Shapiro, R., et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg, 2005;200(4): 505–15; quiz A59–61.CrossRef
64.
Hale G, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998;92(12):4581–90.PubMed
65.
Hale G, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26(1):69–76.PubMedCrossRef
66.
Hale G, et al. Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. Transplantation. 1986;42(3):308–11.PubMedCrossRef
67.
Friend PJ, et al. Campath-1M–prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation. 1989;48(2):248–53.PubMedCrossRef
68.
Friend PJ, et al. Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc. 1991;23(4):2253–4.PubMed
69.
Isaacs JD, et al. CAMPATH-1H in rheumatoid arthritis–an intravenous dose-ranging study. Br J Rheumatol. 1996;35(3):231–40.PubMedCrossRef
70.
71.
Cheung WW, et al. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica. 2006;91(5 Suppl):ECR13.PubMed
72.
Morales J, et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Transplant Proc. 2008;40(9):3223–8.PubMedCrossRef
73.
Watson CJ, et al. Alemtuzumab (CAMPATH 1 H) induction therapy in cadaveric kidney transplantation–efficacy and safety at five years. Am J Transplant. 2005;5(6):1347–53.PubMedCrossRef
74.
Coles AJ, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.PubMedCrossRef
75.
Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant. 2005;5(6):1569–73.PubMedCrossRef
76.
Nankivell BJ, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–33.PubMedCrossRef
77.
Viklicky O, et al. Sequential targeting of CD52 and TNF allows early minimization therapy in kidney transplantation: from a biomarker to targeting in a proof-of-concept trial. PLoS One. 2017;12(1):e0169624.PubMedPubMedCentralCrossRef
78.
Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4(8):1289–95.PubMedCrossRef
79.
Meier-Kriesche HU, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4(3):378–83.PubMedCrossRef
80.
Kwun J, et al. Patterns of De Novo Allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. Am J Transplant. 2012;12(10):2641–51.PubMedPubMedCentralCrossRef
81.
Gareau A, et al. Contribution of B cells and antibody to cardiac allograft vasculopathy. Transplantation. 2009;88(4):470–7.PubMedCrossRef
82.
Kwun J, et al. The role of B cells in solid organ transplantation. Semin Immunol. 2012;24(2):96–108.PubMedCrossRef
83.
Bachmann MF, et al. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol. 1999;29(1):291–9.PubMedCrossRef
84.
Budd RC, et al. Distinction of virgin and memory lymphocytes-t stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic-stimulation. J Immunol. 1987;138(10):3120–9.PubMed
85.
Damle NK, et al. Differential Costimulatory Effects of Adhesion Molecules B7, Icam-1, Lfa-3, and Vcam-1 on Resting and Antigen-Primed Cd4 + Lymphocytes-T. J Immunol. 1992;148(7):1985–92.PubMed
86.
Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol. 2000;164(5):2338–46.PubMedCrossRef
87.
Ford ML, Larsen CP. COvercoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations. Curr Opin Organ Transplant. 2010;15(4):405–10.PubMedPubMedCentralCrossRef
88.
Valujskikh A. The challenge of inhibiting alloreactive T-cell memory. Am J Transplant. 2006;6(4):647–51.PubMedCrossRef
89.
Marco MRL et al. Post-transplant repopulation of naive and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys. Transpl Immunol. 2013;29(1–4):88–98.PubMedCrossRef
90.
Rao SP, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One, 2012;7(6).
91.
Fischer A, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98–109.PubMedCrossRef
92.
Antoine C, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. The Lancet. 2003;361(9357):553–60.CrossRef
93.
Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nature reviews. Clin Oncol. 2010;7(7):415–20.
94.
Alinari L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26(25):3644–53.PubMedCrossRef
95.
Gartner F, et al. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery. CytoTherapy. 2013;15(10):1237–44.PubMedCrossRef
96.
Dunbar EM, et al. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Hematol J. 2008;93(12):1852–8.CrossRef
97.
Slatter MA, et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol. 2008;121(2):361–7.PubMedCrossRef
98.
99.
100.
Ferrara JLM, et al. Graft-versus-host disease. The Lancet. 2009;373(9674):1550–61.CrossRef
101.
Tey SK, et al. Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD. Bone Marrow Transplant. 2016;51(8):1153–5.PubMedCrossRef
102.
Marsh RA, et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127(4):503–12.PubMedCrossRef
103.
Saraf SL, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016;22(3):441–8.PubMedCrossRef
104.
Metadata
Title
The immunological function of CD52 and its targeting in organ transplantation
Authors
Yang Zhao
Huiting Su
Xiaofei Shen
Junfeng Du
Xiaodong Zhang
Yong Zhao
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 7/2017
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-017-1032-8

Other articles of this Issue 7/2017

Inflammation Research 7/2017 Go to the issue

Original Research Paper

Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome

Original Research Paper

Probucol attenuates overt pain-like behavior and carrageenan-induced inflammatory hyperalgesia and leukocyte recruitment by inhibiting NF-кB activation and cytokine production without antioxidant effects

Original Research Paper

Paeonol protects against TNF-α-induced proliferation and cytokine release of rheumatoid arthritis fibroblast-like synoviocytes by upregulating FOXO3 through inhibition of miR-155 expression

Review

Role of microRNAs in sepsis

Original Research Paper

Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis

Short Communication

Mesenchymal stem cells cannot affect mRNA expression of toll-like receptors in different tissues during sepsis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits